Exchange: NASDAQ Sector: Healthcare Industry: Biotechnology
Current Signal: BUY (auto-tracking)
26.94% $10.63
America/New_York / 22 apr 2024 @ 16:00
FUNDAMENTALS | |
---|---|
MarketCap: | 193.41 mill |
EPS: | -1.670 |
P/E: | -6.36 |
Earnings Date: | Apr 30, 2024 |
SharesOutstanding: | 18.20 mill |
Avg Daily Volume: | 0.0881 mill |
RATING 2024-04-22 |
---|
B |
Neutral |
RATINGS | ||
---|---|---|
Rating CashFlow: | Neutral | |
Return On Equity: | Strong Sell | |
Return On Asset: | Sell | |
DE: | Buy | |
P/E: | Sell | |
Price To Book: | Strong Buy |
QUARTER GROWTHS | ||||||
---|---|---|---|---|---|---|
3/22 | 4/22 | 1/23 | 2/23 | 3/23 | 4/23 | |
Revenue | ||||||
Gr.Profit | ||||||
Ebit | ||||||
Asset | ||||||
Debt |
PE RATIO: COMPANY / SECTOR |
---|
0.00x |
Company: PE -6.36 | sector: PE -3.05 |
PE RATIO: COMPANY / INDUSTRY |
---|
-1.08x |
Company: PE -6.36 | industry: PE 5.88 |
DISCOUNTED CASH FLOW VALUE |
---|
$1.304 (-87.72%) $-9.32 |
Date: 2024-04-23 |
Expected Trading Range (DAY) |
---|
$ 9.83 - 11.42 ( +/- 7.47%) |
ATR Model: 14 days |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2023-11-10 | Juda Scott | Buy | 7 000 | Common Stock |
2023-07-12 | Schroeder Timothy J | Sell | 10 000 | Common Stock |
2023-03-17 | Moss David J | Buy | 2 500 | Common Stock |
2023-02-16 | Tesi Raymond Joseph | Buy | 160 000 | Option (right to buy) |
2023-02-16 | Juda Scott | Buy | 35 000 | Option (right to buy) |
INSIDER POWER |
---|
94.47 |
Last 100 transactions |
Buy: 4 257 822 | Sell: 701 956 |
Indicator Signals | |
---|---|
RSI 21 | |
SMA | |
Trend | |
Trend 2 | |
Trend 3 | |
MACD |
Volume Signals | |
---|---|
Price | $10.63 (26.94% ) |
Volume | 0.684 mill |
Avg. Vol. | 0.0881 mill |
% of Avg. Vol | 775.99 % |
Signal 1: | |
Signal 2: |
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
Date | Signal | @ | Closed | % | Feb 14 - 14:15 | buy | $14.50 | N/A | Active |
---|
INmune Bio, Inc., a clinical-stage immunotherapy company, focuses on developing drugs to reprogram the patient's innate immune system to treat disease. The company develops and commercializes product candidates to treat hematologic malignancies, solid tumors, and chronic inflammation. Its development programs include INKmune, which focuses on treating women with relapse refractory ovarian carcinoma and patients with high-risk myelodysplastic syndrome; INB03, an immunotherapy that treats patients with hematologic malignancies and solid tumors; and XPro1595 for the treatment of Alzheimer's disease. The company has license agreements with Xencor, Inc.; Immune Ventures, LLC; University of Pittsburg; and University College London. INmune Bio, Inc. was incorporated in 2015 and is headquartered in Boca Raton, Florida.